Lung Cancer Trials Ask AI to find trials
RecruitingPhase 2 / Phase 3NCT07100080
Official study title

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Study summary

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedIza-bren and Carboplatin

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 9, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 2 / Phase 3

Interventional

Where is it offered?187 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2 / Phase 3
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: Iza-bren; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
EGFR→
Treatment approach
Targeted therapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Non-squamous NSCLC, not amenable to treatment in curative intent.
  • Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
  • Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
  • Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
Reasons someone may not be able to joinExclusion criteria
  • Inadequate organ function and/or bone marrow reserve.
  • Leptomeningeal metastases or spinal cord compression.
  • Poorly controlled systemic medical conditions.
  • Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care buildingIrvine, California
  • University of California, Irvine (UCI) Health - UC Irvine Medical CenterOrange, California
  • Shaw Cancer CenterEdwards, Colorado
  • Local Institution - 0085Gainesville, Florida
  • Local Institution - 0142Pembroke Pines, Florida
  • Piedmont HealthcareAtlanta, Georgia
  • John B Amos Cancer CenterColumbus, Georgia
  • Rush University Medical CenterChicago, Illinois
  • Dana-Farber Cancer InstituteBoston, Massachusetts
  • Washington University School of MedicineSt Louis, Missouri
  • Renown Regional Medical CenterReno, Nevada
  • Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 9, 2026. Always confirm current availability with the study team.

View original record ↗